Facio BioTherapies Pty Limited (“FACIO”) was founded in 2021 in collaboration with the FSHD Global Research Foundation to focus solely on discovering and developing innovative diagnostic solutions and targeted therapies for Facioscapulohumeral Muscular Dystrophy (FSHD).
FACIO is a pre-clinical stage biotechnology company headquartered in Australia, with research collaborations in Melbourne, Sydney, Washington DC, and Seattle Washington.
FSHD Global Research Foundation is a patient-led, philanthropic foundation. Since its inception in 2008, the FOUNDATION has disbursed grants of >$20 million to enable discovery, diagnostic, biomarker and clinical research.
FSH muscular dystrophy (FSHD) is a highly complex muscle wasting disease causing progressive weakness that affects over one million people globally. The condition is caused by a toxic gain of function genetic alteration in a transcription factor (DUX4) that is normally silenced after embryonic development. Currently there are no approved treatments for FSHD and the condition suffers from lack of investment in basic and translational research.
FACIO's VISION is to transform the standard of care and to ultimately cure FSHD.
Our MISSION is to develop best-in-disease, targeted therapies that: 1) modify the toxic genes that cause FSHD, 2) are muscle tissue targeting 3) have disease modifying potential, 4) are safe and well tolerated and 5) are durable in mechanism of action.
FACIO is connecting with FSHD Patient Advocacy Groups in Australia and Globally to ensure we embed the patient voice and experience in co-designing solutions, and to access enablers of innovation. This connection informs our science and how we think about addressing unmet patient needs.
Under a strategic collaboration with FSHD Global Research Foundation, FACIO is committed to evaluating IP created by its research partners and to creating a commercialisation pathway for projects supported by the FOUNDATION.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Sydney, Nsw, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://faciobt.com
- Keywords
- Biotechnology, neuromuscular disease, biomarkers, biopharmaceuticals, nucleic acid therapies, commercialisation, scientific affairs, discovery, chemistry, neurodegeneration, regeneration, muscle biology, genomics, diagnostics, market access, regulatory affairs.
- HQ
- Sydney, NSW
Facio Biotherapies Pty Ltd Questions
Facio Biotherapies Pty Ltd's website is http://faciobt.com
Facio Biotherapies Pty Ltd's LinkedIn profile is https://au.linkedin.com/company/facio-biotherapies
Facio Biotherapies Pty Ltd has
6 employees.
View email and phone details for 6
employees at Facio Biotherapies Pty Ltd.
Facio Biotherapies Pty Ltd's industry is
Biotechnology Research
Facio Biotherapies Pty Ltd's top competitors are
Dr Michael Freelander Mp,
St Andrews Cathedral Foundation,
Gi Asia Pacific,
Well Founded,
Stiltech Sa,
Biopharmadispatch,
Yara Law Pty Ltd,
Rainbow Wholefoods,
Raydel,
Fshd Global Research Foundation.
Facio Biotherapies Pty Ltd's categories are Biotechnology Research
Facio Biotherapies Pty Ltd's founding year is 2021
